Skeletal muscle cells expressing VEGF induce capillary formation and reduce cardiac injury in rats

In situ delivery of bone marrow cells and mesenchymal stem cells improves cardiovascular function in hypertensive rats submitted to myocardial infarction

“…Capillary density was evaluated adjacent to the cardiac scars as the total number of capillaries in the fields, expressed as number of capillaries per field (units/mm 2 ) [5].…”

“…Experimental studies have suggested that stem cells can exert beneficial effects on the failing heart by transdifferentiating into cardiac cell types and/or by providing a source of cardioprotective paracrine factors [4]. Several adult stem cell types [5][6][7][8][9], animal models [10,11] and delivery pathways [12][13][14] have been tested in the last years, in the search for ideal conditions which were not yet found. Bone marrow cells (BMCs) [15] and cultured mesenchymal stem cells (MSCs) [3,16], administered mainly by in situ injection [10], are the most frequently used types of cells.…”

Relevância e tratamento das lesões características da insuficiência cardíaca na musculatura esquelética

“…[99][100][101][102] Por fim, é importante ressaltar que começam a aparecer na literatura resultados promissores em modelos animais e pacientes submetidos a terapias celulares em relação ao tecido muscular cardíaco na insuficiência cardíaca. 103 No entanto, devido à importância da musculatura esquelética na síndrome, discutida no início do presente estudo, em breve terapias celulares e gênicas provavelmente começarão a ser testadas com o objetivo de reverter a deterioração desse tecido. Em relação à terapia gênica, potencialmente várias manipulações genéticas podem ser benéficas, como das proteínas que transportam o Ca 2+ , participam dos processos de síntese e degradação protéicas, e regulam a angiogênese.…”

Intramyocardial transplantation of fibroblasts expressing vascular endothelial growth factor attenuates cardiac dysfunction

“…[17][18][19][20][21] Along with others, we have shown earlier that genetically modified skeletal myoblasts (SKs) expressing VEGF used as vectors and transplanted in a relative small number can increase capillary density and decreases myocardial scaring in rats when injected 1 week before ischemia/ reperfusion injury. 22 This early success occurs even though the expression of the transgene lasts only about 7-14 days when myoblasts are used as vectors. 22 In this study, we hypothesized that transplantation of syngeneic fibroblasts as 'vector' to deliver angiogenic factors can support longer-lasting transgene expression and that association of these cells with a fibrin biopolymer would increase cell retention and the local levels of the growth factors.…”